Business Context and Reporting Period
Company: Nature's Sunshine Products, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2001
Business Overview: The Company manufactures and distributes nutritional supplements and herbal products through a direct sales network of independent Managers and Distributors. Operations are segmented geographically into the United States, Latin America, Asia Pacific, and Other markets.
Key Financial Metrics
Amounts in thousands, except per-share data.
| Metric | Three Months Ended June 30, 2001 |
Six Months Ended June 30, 2001 |
|---|---|---|
| Sales | $81,760 | $163,454 |
| Net Income | $4,696 | $8,718 |
| Diluted EPS | $0.28 | $0.53 |
| Operating Cash Flow | N/A | $16,227 |
| Cash and Equivalents | $30,995 (Ending Balance) | $30,995 (Ending Balance) |
| Short-Term Debt | $112 | $112 |
| Working Capital | $40,565 | $40,565 |
Margins (Six Months Ended June 30, 2001):
- Gross Margin (Sales less COGS): 82.1%
- Operating Margin: 8.1%
- Net Profit Margin: 5.3%
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 2.6% for the quarter and 1.5% for the six-month period compared to the prior year. International sales grew 6.3% year-over-year for the six months, offsetting a 2.1% decline in U.S. sales.
- Profitability Decline: Net income decreased 4.0% for the quarter and 7.1% for the six-month period. Operating income declined 11.9% (quarter) and 9.9% (six months) due to increased operating expenses.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 6.7% (quarter) and 5.1% (six months), primarily driven by integration costs associated with the acquisition of Synergy Japan.
- Regional Performance:
- Latin America: Sales decreased 6.8% (quarter) due to Brazilian government import restrictions on nutritional supplements.
- Asia Pacific: Sales increased 13.9% (six months), driven by growth in South Korea and Synergy Japan.
- Other Markets: Sales increased 21.0% (six months), led by operations in Russia and Israel.
- Cash Flow: Net cash provided by operating activities increased to $16.2 million for the six months ended June 30, 2001, compared to $13.3 million in the prior year period.
Outlook, Risks, and Management Commentary
- Guidance: Management expects Cost of Goods Sold (COGS) and Volume Incentives to remain relatively constant as a percentage of sales for the remainder of 2001. SG&A expenses are expected to decrease slightly as a percentage of sales due to increased sales volume and cost controls.
- Capital Expenditures: The Company is expanding its manufacturing and R&D facility. Total project cost is estimated at $14.0 million, with $9.4 million paid as of June 30, 2001. Completion is scheduled for Q2 2002.
- Strategic Investments: The Company entered an exclusive manufacturing agreement with Cetalon Corporation and purchased $1.5 million of Cetalon common stock, with an option to purchase an additional $0.5 million exercised subsequent to the reporting period.
- Risks:
- Foreign Currency: Approximately 44.2% of revenue is generated outside the U.S. A strengthening U.S. dollar negatively impacts reported sales and expenses.
- Regulatory: Ongoing regulatory restrictions in Brazil continue to negatively impact sales in that region.
- Liquidity: While current cash and internally generated funds are sufficient, a prolonged economic downturn could adversely affect long-term liquidity.
Investor Verification Checklist
- Verify the impact of Brazilian import regulations on the sustainability of Latin American sales.
- Monitor the integration costs and revenue contribution of the Synergy Japan acquisition.
- Assess the progress and final cost of the $14.0 million facility expansion project.
- Review the performance of the Cetalon Corporation investment and manufacturing agreement.
- Track foreign currency exchange rate fluctuations, particularly in Brazil, Japan, and South Korea, given the 44.2% international revenue exposure.